Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy
Stuart Spencer(AstraZeneca (United Kingdom)), Juliane M. Jürgensmeier(AstraZeneca (United Kingdom)), Simon T. Barry(AstraZeneca (Singapore)), Shethah Morgan(AstraZeneca (United Kingdom)), Jane Robertson(Cancer Research UK), Paulo M. Hoff(Translational Research in Oncology), Aurélien Pommier(Centre National de la Recherche Scientifique)
Cited by 32
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
|Cancer Research|2013|1.5k
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
|Advanced Drug Delivery Reviews|2016|1.1k
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
|The Lancet Oncology|2012|526
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303